Do analysts prefer INKT or FTFT?

MiNK Therapeutics presently has a consensus price target of $35.00, indicating a potential upside of 196.11%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe MiNK Therapeutics is more favorable than Future FinTech Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Future FinTech Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to INKT or ALEC?

In the previous week, MiNK Therapeutics had 8 more articles in the media than Alector. MarketBeat recorded 9 mentions for MiNK Therapeutics and 1 mentions for Alector. Alector's average media sentiment score of 1.67 beat MiNK Therapeutics' score of 1.05 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alector 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer TNXP or INKT?

In the previous week, MiNK Therapeutics had 5 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 9 mentions for MiNK Therapeutics and 4 mentions for Tonix Pharmaceuticals. MiNK Therapeutics' average media sentiment score of 1.05 beat Tonix Pharmaceuticals' score of 0.24 indicating that MiNK Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral MiNK Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INKT or KROS?

In the previous week, MiNK Therapeutics and MiNK Therapeutics both had 9 articles in the media. MiNK Therapeutics' average media sentiment score of 1.05 beat Keros Therapeutics' score of 0.54 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, RNA or INKT?

Avidity Biosciences is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avidity Biosciences N/A N/A N/A -$2.15 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.40 N/A

Is RNA or INKT more profitable?

Company Net Margins Return on Equity Return on Assets Avidity Biosciences N/A N/A N/A MiNK Therapeutics N/A N/A -92.37%

Does the media refer more to RNA or INKT?

In the previous week, Avidity Biosciences had 2 more articles in the media than MiNK Therapeutics. MarketBeat recorded 11 mentions for Avidity Biosciences and 9 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.05 beat Avidity Biosciences' score of 0.90 indicating that MiNK Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiNK Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MiNK Therapeutics (INKT) Competitors

$11.82 -0.38 (-3.11%)

Closing price 04:00 PM Eastern

Extended Trading

$11.73 -0.09 (-0.79%)

As of 06:00 PM Eastern

Compare

INKT vs. FTFT, ALEC, TNXP, KROS, and RNA

Should you buy MiNK Therapeutics stock or one of its competitors? MiNK Therapeutics's main competitors and comparable companies include Future FinTech Group (FTFT), Alector (ALEC), Tonix Pharmaceuticals (TNXP), Keros Therapeutics (KROS), and Avidity Biosciences (RNA). Companies are selected based on similarities in market, industry, and size.

How does MiNK Therapeutics compare to Future FinTech Group?

MiNK Therapeutics (NASDAQ:INKT) and Future FinTech Group (NASDAQ:FTFT) are related small-cap companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

MiNK Therapeutics presently has a consensus price target of $35.00, indicating a potential upside of 196.11%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe MiNK Therapeutics is more favorable than Future FinTech Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Future FinTech Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MiNK Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Future FinTech Group has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

Future FinTech Group has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Future FinTech Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Future FinTech Group	$3.83M	0.31	-$4.62M	-$7.54	N/A

MiNK Therapeutics has a net margin of 0.00% compared to Future FinTech Group's net margin of -157.53%. MiNK Therapeutics' return on equity of 0.00% beat Future FinTech Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Future FinTech Group	-157.53%	-12.22%	-10.08%

In the previous week, MiNK Therapeutics had 9 more articles in the media than Future FinTech Group. MarketBeat recorded 9 mentions for MiNK Therapeutics and 0 mentions for Future FinTech Group. MiNK Therapeutics' average media sentiment score of 1.05 beat Future FinTech Group's score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MiNK Therapeutics	Positive
Future FinTech Group	Neutral

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Future FinTech Group shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Future FinTech Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

MiNK Therapeutics beats Future FinTech Group on 10 of the 15 factors compared between the two stocks.

How does MiNK Therapeutics compare to Alector?

MiNK Therapeutics (NASDAQ:INKT) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by insiders. Comparatively, 8.3% of Alector shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MiNK Therapeutics currently has a consensus target price of $35.00, indicating a potential upside of 196.11%. Alector has a consensus target price of $3.63, indicating a potential upside of 57.61%. Given MiNK Therapeutics' higher probable upside, research analysts clearly believe MiNK Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

MiNK Therapeutics has a net margin of 0.00% compared to Alector's net margin of -850.13%. MiNK Therapeutics' return on equity of 0.00% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Alector	-850.13%	-531.03%	-44.00%

In the previous week, MiNK Therapeutics had 8 more articles in the media than Alector. MarketBeat recorded 9 mentions for MiNK Therapeutics and 1 mentions for Alector. Alector's average media sentiment score of 1.67 beat MiNK Therapeutics' score of 1.05 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alector	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

MiNK Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Alector has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

MiNK Therapeutics has higher earnings, but lower revenue than Alector. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Alector	$21.05M	12.20	-$142.93M	-$1.10	N/A

Summary

Alector beats MiNK Therapeutics on 9 of the 15 factors compared between the two stocks.

How does MiNK Therapeutics compare to Tonix Pharmaceuticals?

Tonix Pharmaceuticals (NASDAQ:TNXP) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Tonix Pharmaceuticals currently has a consensus price target of $24.50, indicating a potential upside of 96.79%. MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 196.11%. Given MiNK Therapeutics' higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MiNK Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. MiNK Therapeutics' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%
MiNK Therapeutics	N/A	N/A	-92.37%

In the previous week, MiNK Therapeutics had 5 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 9 mentions for MiNK Therapeutics and 4 mentions for Tonix Pharmaceuticals. MiNK Therapeutics' average media sentiment score of 1.05 beat Tonix Pharmaceuticals' score of 0.24 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
MiNK Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MiNK Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	16.29	-$124.02M	-$12.94	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A

Tonix Pharmaceuticals has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Summary

MiNK Therapeutics beats Tonix Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does MiNK Therapeutics compare to Keros Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

MiNK Therapeutics currently has a consensus target price of $35.00, suggesting a potential upside of 196.11%. Keros Therapeutics has a consensus target price of $20.50, suggesting a potential upside of 90.17%. Given MiNK Therapeutics' higher probable upside, research analysts plainly believe MiNK Therapeutics is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

MiNK Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. MiNK Therapeutics' return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

In the previous week, MiNK Therapeutics and MiNK Therapeutics both had 9 articles in the media. MiNK Therapeutics' average media sentiment score of 1.05 beat Keros Therapeutics' score of 0.54 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Keros Therapeutics has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Keros Therapeutics	$244.06M	0.88	$87.01M	-$3.70	N/A

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

MiNK Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Summary

Keros Therapeutics beats MiNK Therapeutics on 8 of the 14 factors compared between the two stocks.

How does MiNK Therapeutics compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

In the previous week, Avidity Biosciences had 2 more articles in the media than MiNK Therapeutics. MarketBeat recorded 11 mentions for Avidity Biosciences and 9 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.05 beat Avidity Biosciences' score of 0.90 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiNK Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
MiNK Therapeutics	N/A	N/A	-92.37%

Avidity Biosciences is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A

Avidity Biosciences currently has a consensus target price of $63.85, indicating a potential upside of 368.77%. MiNK Therapeutics has a consensus target price of $35.00, indicating a potential upside of 196.11%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Avidity Biosciences is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

2.9% of MiNK Therapeutics shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Avidity Biosciences beats MiNK Therapeutics on 7 of the 11 factors compared between the two stocks.

Get MiNK Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INKT vs. The Competition

Export

Metric	MiNK Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$62.26M	$4.01B	$7.36B	$12.81B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-4.92	11.69	270.55	24.05
Price / Sales	N/A	1,377.21	630.76	95.90
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	-3.90	17.26	11.18	6.40
Net Income	-$12.49M	-$22.72M	$3.46B	$347.95M
7 Day Performance	5.35%	2.89%	1.98%	0.91%
1 Month Performance	6.78%	9.74%	7.32%	5.10%
1 Year Performance	-20.67%	54.81%	24.76%	16.16%

MiNK Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INKT MiNK Therapeutics	3.1858 of 5 stars	$11.82 -3.1%	$35.00 +196.1%	-18.1%	$62.26M	N/A	N/A	30	Positive News
FTFT Future FinTech Group	0.786 of 5 stars	$0.83 +1.5%	N/A	-98.1%	$1.52M	$3.83M	N/A	70	Positive News
ALEC Alector	2.3506 of 5 stars	$1.96 -3.9%	$3.63 +84.9%	-6.3%	$218.85M	$13.86M	N/A	270	Gap Down
TNXP Tonix Pharmaceuticals	3.6026 of 5 stars	$12.71 +1.7%	$24.50 +92.8%	-67.0%	$214.39M	$13.11M	N/A	50
KROS Keros Therapeutics	3.8789 of 5 stars	$10.10 -5.3%	$20.50 +103.0%	-29.1%	$211.36M	$15.01M	N/A	100	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INKT) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, ALEC, TNXP, KROS, and RNA

How does MiNK Therapeutics compare to Future FinTech Group?

Summary

How does MiNK Therapeutics compare to Alector?

Summary

How does MiNK Therapeutics compare to Tonix Pharmaceuticals?

Summary

How does MiNK Therapeutics compare to Keros Therapeutics?

Summary

How does MiNK Therapeutics compare to Avidity Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, ALEC, TNXP, KROS, and RNA

How does MiNK Therapeutics compare to Future FinTech Group?

Do analysts prefer INKT or FTFT?

Which has more volatility & risk, INKT or FTFT?

Which has preferable earnings & valuation, INKT or FTFT?

Is INKT or FTFT more profitable?

Does the media refer more to INKT or FTFT?

Do institutionals & insiders believe in INKT or FTFT?

Summary

How does MiNK Therapeutics compare to Alector?

Do insiders & institutionals believe in INKT or ALEC?

Do analysts prefer INKT or ALEC?

Is INKT or ALEC more profitable?

Does the media refer more to INKT or ALEC?

Which has more volatility and risk, INKT or ALEC?

Which has stronger valuation & earnings, INKT or ALEC?

Summary

How does MiNK Therapeutics compare to Tonix Pharmaceuticals?

Do analysts prefer TNXP or INKT?

Is TNXP or INKT more profitable?

Does the media prefer TNXP or INKT?

Do institutionals and insiders have more ownership in TNXP or INKT?

Which has preferable valuation and earnings, TNXP or INKT?

Which has more risk & volatility, TNXP or INKT?

Summary

How does MiNK Therapeutics compare to Keros Therapeutics?

Do analysts recommend INKT or KROS?

Is INKT or KROS more profitable?

Does the media favor INKT or KROS?

Which has better earnings and valuation, INKT or KROS?

Do institutionals & insiders have more ownership in INKT or KROS?

Which has more volatility and risk, INKT or KROS?

Summary

How does MiNK Therapeutics compare to Avidity Biosciences?

Does the media refer more to RNA or INKT?

Is RNA or INKT more profitable?

Which has stronger earnings and valuation, RNA or INKT?

Do analysts rate RNA or INKT?

Do institutionals & insiders believe in RNA or INKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools